company background image
CNTA

Centessa Pharmaceuticals NasdaqGS:CNTA Stock Report

Last Price

US$4.02

Market Cap

US$379.2m

7D

-7.4%

1Y

-75.7%

Updated

30 Sep, 2022

Data

Company Financials +
CNTA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CNTA Stock Overview

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients.

Centessa Pharmaceuticals plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Centessa Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.02
52 Week HighUS$17.73
52 Week LowUS$2.89
Beta0
1 Month Change-7.59%
3 Month Change-22.24%
1 Year Change-75.67%
3 Year Changen/a
5 Year Changen/a
Change since IPO-81.52%

Recent News & Updates

Sep 14

Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Centessa Pharmaceuticals' (NASDAQ:CNTA) SerpinPC to treat hemophilia B. The U.K.-based company said in a Sept. 14 press release that it plans to begin registrational studies of SerpinPC in Q4 2022. SerpinPC is a biological drug candidate, based on the serpin family of proteins which is designed to allow more thrombin to be generated by inhibiting activated protein C (APC), thus rebalancing coagulation in patients with hemophilia, according to Centessa. "We believe SerpinPC has the potential to offer patients with hemophilia B a convenient subcutaneous option that is designed to prevent and reduce bleeds without the risk of thrombosis," said Centessa CEO Saurabh Saha. The FDA grants orphan drug status to therapies which treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including up to seven years of market exclusivity, if approved.

Aug 10

Centessa Pharmaceuticals GAAP EPS of -$0.69

Centessa Pharmaceuticals press release (NASDAQ:CNTA): Q2 GAAP EPS of -$0.69. Cash and Cash Equivalents: $484.2 million as of June 30, 2022, which the Company expects will fund operations into 2026, without drawing on the remaining available tranches under the Oberland credit facility.

Shareholder Returns

CNTAUS BiotechsUS Market
7D-7.4%0.4%-2.5%
1Y-75.7%-25.6%-23.2%

Return vs Industry: CNTA underperformed the US Biotechs industry which returned -25.8% over the past year.

Return vs Market: CNTA underperformed the US Market which returned -21.5% over the past year.

Price Volatility

Is CNTA's price volatile compared to industry and market?
CNTA volatility
CNTA Average Weekly Movement12.9%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: CNTA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: CNTA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
202068Saurabh Sahahttps://www.centessa.com

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases.

Centessa Pharmaceuticals plc Fundamentals Summary

How do Centessa Pharmaceuticals's earnings and revenue compare to its market cap?
CNTA fundamental statistics
Market CapUS$379.24m
Earnings (TTM)-US$220.09m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CNTA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$220.09m
Earnings-US$220.09m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.33
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio16.0%

How did CNTA perform over the long term?

See historical performance and comparison